Cite

HARVARD Citation

    Guida, A. et al. (n.d.). 2626 Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): Retrospective analysis. European journal of cancer. pp. S521-. [Online]. 
  
Back to record